Kontakt

Prof. Dr. med. Ingo Brink
Chefarzt
Qualifikation: Facharzt für Nuklearmedizin
Schwerpunkt: Nuklearmedizin, PET/CT, Schilddrüsenerkrankungen, Umgang mit offenen radioaktiven Stoffen in Diagnostik und Therapie, Röntgendiagnostik einschließlich Computertomographie für Personen mit Fachkunde „offene radioaktive Stoffe“
Portraitfoto Prof. Dr. med. Ingo Brink

Beruflicher Werdegang

  • Studium der Humanmedizin an der Medizinischen Fakultät  (Charité) der Humboldt-Universität  zu Berlin (Staatsexamen) 1986-1992                 
  • Arzt im Praktikum an der Medizinischen Klinik III des Zentrums für Innere Medizin der Charité Berlin 01/1993 - 06/1994           
  • Assistenzarzt der Medizinischen Klinik III der Charité Berlin 07/1994 - 02/1995         
  • „Postdoctoral fellow“ am Scripps Research Institute, La Jolla, USA  03/1995 - 12/1996         
  • Assistenzarzt der Abteilung für Nuklearmedizin, Radiologische Klinik der Universitätsklinik Freiburg 01/1997 – 06/2000    
  • Oberarzt der Abteilung für Nuklearmedizin, Radiologische Klinik der Universitätsklinik Freiburg 07/2000 – 12/2002       
  • Leitender Oberarzt der Abteilung für Nuklearmedizin, Radiologische Klinik der Universitätsklinik Freiburg 01/2003 – 09/2008                
  • Kommissarischer Ärztlicher Direktor der Abteilung für Nuklearmedizin, Radiologische Klinik der Universitätsklinik Freiburg 04/2007 – 07/2007
  • Chefarzt der Klinik für nuklearmedizinische Diagnostik und Therapie des Klinikums Ernst von Bergmann Potsdam seit 10/2008
  • Parallel ambulante Tätigkeit als Nuklearmediziner im MVZ Nuklearmedizin des Klinikum EvB seit 01/2009

Wissenschaftliche Tätigkeiten

  • Diplom: Thema: "Wirkung von Ro-(SS-A)-Antikörpern und UVA auf Keratinozyten in vitro", 11/1991
  • Dissertation: Thema: "Therapie mit monoklonalen Anti-CD4-Antikörpern bei schweren Verlaufsformen des SLE“ Akademischer Grad: Dr. med. 06/1995
  • Robert-Koch-Preis der Charité Berlin 1996
  • Habilitation: Thema: "Studien zur klinischen Wertigkeit der Positronen-Emissions-Tomographie bei  Tumoren von Thorax und Hals“, Akademischer Grad: Privat-Dozent Dr. med 01/2005           
  • Ernennung zum Außerplanmäßigen Professor 04/0207 der Albert-Ludwigs-Universität Freiburg
  • 75 begutachtete Fachpublikationen auf dem Gebiet der Tumordiagnostik, Nuklearmedizin und Immunologie
  • Mitglied im wissenschaftlichen Beirat der Zeitschrift “Angewandte Nuklearmedizin”
  • Leiter der Ärztlichen Stelle Brandenburg für die Qualitätssicherung nach § 83 Abs. 1 der StrSchV
  • Beratendes Mitglied der Qualitätssicherungskommission Radiologie der KV Brandenburg
  • Gutachter der LÄK Brandenburg

Mitgliedschaften

  • DGN (Deutsche Gesellschaft für Nuklearmedizin)
  • BBGN (Berlin-Brandenburgische Gesellschaft für Nuklearmedizin)
  • SWN (Südwestdeutsche Gesellschaft für Nuklearmedizin)

Weiterbildungsbefugnis

Nuklearmedizin einschließlich PET/CT (5 Jahre)

Publikationen

  • Brink I, Hubalewska-Dydejczyk A: Comment on Sundin et al.: ENETS Consensus Guidelines. Neuroendocrinology 2019; 108(4):365
  • Brink I, Hentschel M, Hartmut P.H. Neumann HPH, Schäfer O, Moser E: FDOPA-PET als Paradigma molekularer Bildgebung in der Onkologie. Der Nuklearmediziner 2007; 30: 70-82
  • Brink I, Schaefer O, Walz M, Neumann HPH: Fluorine-18 DOPA PET imaging of paraganglioma syndrome. Clin Nucl Med 2006, 31: 39-41   
  • Brink I, Schumacher T, Mix M, Ruhland S, Stoelben E, Digel W, N. Ghanem, E. Moser, Nitzsche EU: Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med 2004, 21(12): 1614-1620                 
  • Brink I, Kleimaier M, Hentschel M, Bley TA, Walch A, Mix M, Moser E, Imdahl A: Therapy-induced esophagitis limits the predicative value of 18F-FDG-PET in esophageal carcinoma with respect to response to a neoadjuvant radio/chemotherapy. EJSO 2004, 30:544-550  
  • Brink I, Högerle S, Klisch, Bley TA: Imaging of pheochromocytoma and paragaglioma. Familial cancer 2005, 4: 61-68 
  • Brink I, E.U. Nitzsche, M. Mix, T. Schindler, M. Hentschel, S. Högerle, E. Moser: Optimaler Akquisitionszeitpunkt für die Herz-PET mit 18F-FDG oraler Glukosebelastung. Nuklearmedizin 2003, 42: 39-44
  • Brink I, Klenzner T, Krause T, Mix M, Ross U, Moser E, Nitzsche EU: Lymph node staging in extracranial head and neck cancer with FDG PET – what is the appropriate uptake period? Nuklearmedizin 2002, 41:108-113 
  • Brink I, Hoegerle S, Schneider B: Enormous bilateral 18F-FDG-uptake in suprarenal glands caused by Non-Hodgkin‘s lymphoma. Clin Nucl Med 2002, 27:739-740    
  • Brink I, Reinhardt M, Högerle S, Altehoefer C, Moser EA, Nitzsche EU: Increased metabolic activity in the thymus gland studied with FDG PET – age-dependency and frequency after chemotherapy. J Nucl Med 2001, 42(4): 591-595 
  • Brink I, Moser E.: Nuklearmedizinische Diagnostik und Therapie von Skelettmetastasen. Klinikarzt 2000, 29: 276-280 (review)
  • Brink I., T. Schumacher, J. Talazko, P. Reuland, M. Mix, T. Schindler, E. Moser, E.U. Nitzsche: 3D-Cardiac-PET - A recommendable clinical alternative to 2D-cardiac-PET? Clinical Positron Imaging 1999, 2:191-196   
  • Brink I., B. Thiele, G.-R. Burmester, G. Trebeljahr, F. Emmrich, F. Hiepe: Effects of anti-CD4-antibodies on the release of IL-6 and TNF- a in whole blood samples from SLE-patients. Lupus 1999, 8:723-730  
  • Brink I. Böhm F. Meffert H. Sönnichsen N. [Cytotoxic effect on human keratinocytes caused by anti-Ro-(SS-A) antibodies and UVA in vitro]. [German] Dermatologische Monatsschrift. 176(11):701-6, 1990.
  • Rekowski J, Hüttmann A, Schmitz C, Müller SP, Kurch L, Kotzerke J, Franzius C, Weckesser M, Bengel FM, Freesmeyer M, Hertel A, Krohn T, Holzinger J, Brink I, Haberkorn U, Nyuyki F, van Assema DME, Geworski L, Hasenclever D, Jöckel KH, Dührsen U..: Interim PET evaluation in diffuse large B-cell lymphoma employing published recommendations: Comparison of the Deauville 5-point scale and the SUVmax method. J Nucl Med 2021, 62:37-42
  • Verburg FA, Amthauer H, Binse I, Brink I, Buck A, Darr A, Dierks C, Koch Cm König U, Kreissl MC, Luster M, Reuter C, Scheidhauer K, Willenberg HS, Zielke A, Schott M:  Questions and controversies in the clinical application of tyrosine kinase inhibitors to treat patients with radioiodine-refractory differentiated thyroid carcinoma: expert perspectives. Hormon metab res 2020, 53:149-160
  • Andreas Hüttmann, ……., Georg Maschmeyer, Ingo Brink, …. Ulrich Dührsen. Six versus eight doses of rituximab in R-CHOP-treated patients with aggressive B-cell lymphoma and a favourable interim positron emission tomography scan: a subgroup analysis of the PETAL trial Ann Haematol 2019; 98:897-907
  • Ulrich Dührsen, ……. Georg Maschmeyer, Ingo Brink, ……. and Andreas Hüttmann, on behalf of the PETAL Positron-emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase 3 trial. trial investigators. J Clin Oncol 2018; 36: 2024-2034
  • Maschmeyer G, Brink I, Jähne D, Arnold R, Schega O.: Residual thymic tissue and lymph node involvement by acute myeloid leukaemia presenting as mediastinal, strongly 18 FDG-PET-positive masses. Eur J Haematol. 2017; 99:286-288
  • Klar M, Bossart M, , Stickeler E, , Brink I, Orlowska-Volk M, Denschlag D:  Sentinel lymph node detection in patients with vulvar carcinoma; Feasibility of intra-operative mapping with technetium-99m-labeled nanocolloid Eur J Surg Oncol 2011; 37: 818-23
  • Michael Hentschel M, Rottenburger C, Neumann HPH, Brink I: Is there an optimal scan time for 6-F-18-Fluoro-L-DOPA PET in Pheochromocytomas and Paragangliomas? Clin Nucl Med 2012; 37: e24-29
  • Wild D, Weber WA, Mäcke H, Brink I, Behe, M. First clinical evidence that somatostatin receptor antagonists may be preferable to agonists for tumor targeting. JNM 2011; 52:1412-17
  • Rottenburger C, Hentschel M, Kelly T, Trippel M, Brink I, Reithmeier T, Meyer P, Nikkhah G: Comparison of C-11 methionine and C-11 choline for PET imaging of brain metastases: A prospective pilot study. Clin Nucl Med 36(8):639-642, August 2011.
  • Klar M, Meyer PT, Hancke K, Brink I, Orlowska-Volk M, Gitsch G, Denschlag D: Evaluation of FDG-PET for detecting lymph node metastasis in uterine corpus cancer. Anticancer Res. 2010 Sep; 30(9):3787-90.
  • Pasquet S, Sovalat H, Hénon P, Bischoff N, Arkam Y, Ojeda-Uribe M, Bouar R, Rimelen V, Brink I, Dallemand R, Monassier JP.: Long-term benefit of intracardiac delivery of autologous granulocyte-colony-stimulating factor-mobilized blood CD34+ cells containing cardiac progenitors on regional heart structure and function after myocardial infarct. Cytotherapy. 2009;11(8):1002-15
  • Plathow C, Aschoff P, Lichy MP, Eschmann S, Hehr T, Brink I, Claussen CD, Pfannenberg C, Schlemmer HP: Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer--initial results. Invest Radiol. 2008; 43 :290-297
  • Schwab K.O., Pfarr N, van der Werf-Grohmann N, Fassnacht U, Pohl M, Brink I, Jüttner E, Rädecke J, Rückauer KD, Winter J, Musholt T, Pohlenz J: Autonomous thyroid adenoma: Only an adult disease? Horm Res, 2008; 70 Suppl. 1: 41-42
  • Geiger J, Walter K, Uhl M, Bley TA, Jüttner E, Brink I, Kirschbaum A, Langer M, Kontny U: Imaging findings in a 3-year-old girl with type III pleuropulmonary blastoma. In vivo 2007, 21:1119-1122
  • Chao MM, Niemeyer CM, Brink I, Göhring G, Jüttner E, Strahm B: Extramedullary relapse of therapy-related myelodysplastic syndrome following donor leukocyte infusion: Case report and review of graft-versus leukemia. Ann Hematol 2008; 87: 165-166.
  • Ghanem NA, Pache G, Lohrmann C, Brink I, Bley T, Kotter E, Kelly T, Langer M. MRI and (18)FDG-PET in the assessment of bone marrow infiltration of the spine in cancer patients. Eur Spine J. 2007; 16:1907-1912
  • Neumann HPH, Cybulla M, Gläsker S, Coulin C, Van Velthoven V, Berlis A, Hader C, Schäfer O, Treier M, Brink I, Schultze-Seemann W, Leiber C, Rückauer K, Junker B,  Agostini HJ, Hetzel A, Boedeker CC: Von Hippel-Lindau disease. Interdisciplinary patient care. Interdisziplinäre Patientenversorgung. Spektrum Augenheilkd 2007; 21(5): 271-278
  • Hentschel M, Paulus T, Mix M, Moser E, Nitzsche EU, Brink I.: Analysis of blood flow and glucose metabolism in mammary carcinomas and normal breast. A 15O-H2O- and 18F-FDG-study. Nucl Med Comm 2007, 28: 789-797
  • Hentschel M, Paul D, Moser E, Brink I: Möglichkeiten und Grenzen der modernen Schnittbildverfahren (CT, MRT, PET) in der Molekularen Bildgebung. Der Nuklearmediziner 2007; 30: 31-41
  • Neumann HPH, Cybulla M, Gläsker S, Coulin C, van Velthoven V, Berlis A, Hader C, Schäfer O, Treier M, Brink I, Schultze-Seemann W, Leiber C, Rückauer K, Junker B, Agostini H, Hetzel A, Bödeker C: Von-Hippel-Lindau Erkrankung Interdisziplinäre Patienten-Versorgung. Ophthalmologe 2007; 104: 119-126
  • Walker UA, Garve K, Brink I, Miehle N, Peter HH, Kelly T: (99m)Technetium pyrophosphate scintigraphy in the detection of skeletal muscle disease. Clin Rheumatol 2007; 26: 1119-1122
  • Lange-Nolde A, Zajic T, Slawik M, Brink I, Moser E, Högerle S.. Positron emission tomography with [18F]F-DOPA in the imaging of parathyroid adenoma in patients with primary hyperparathyroidism: preliminary results. Nukmed 2006, 45: 193-196
  • Bley T, Brink I, Reinhard M: Bildgebende Verfahren bei Riesenzellarteriitis (Arteriitis temporalis, Arteriitis cranialis). Ophthalmologe 2006, 103: 308-316
  • Bausch B, Boedeker CC, Berlis A, Brink I, Walz MK, Januszewicz A, Opocher G, Eng C, Neumann HPH: Genetic and clinical investigation of pheochromocytoma: a 22-year experience, from Freiburg, Germany to international effort. Ann NY Acad Sci 2006, 1073: 122-137
  • Györke T, Zajic T, Lange A, Makó, Moser E, Brink I: Impact of  FDG-PET for staging of Ewing sarcomas and Primitive Neuro Ectodermal Tumors. Nucl Med Communication 2006,  27:17-24
  • Müller AMS, Rawluk J, Thierry V, Brink I, Engelhardt M: Innovative Antikörper-Therapien bei malignen Lymphomen. Dt Med Wochenschr 2005, 130(48): 2783-2788    
  • Hentschel M, Müller F, Brink I: Potentials and limits of combined anatomical and functional imaging modalities in tumor diagnosis. In: K. Conrad, M. Bachmann, W. Lehmann, U. Sack (Eds.) Methods, Possibilities and Perspectives of Pre-symptomatic Tumor Diagnostics. Pabst Science Publisher, Lengerich, Deutschland, 2005: 297-305
  • Schiavi F, Boedeker CC, Bausch B, Peçzkowska M, Gomez CF, Straßburg T, Pawlu C, Buchta M, Salzmann M, Hoffmann MM, Berlis A, Brink I, Cybulla M, Muresan M, Walter MA, Forrer F, Välimäki M, Kawecki A, Szutkowski Z, Schipper J, Walz MK, Pigny P, Bauters C, Willet-Brozick JE, Baysal BE, Januszewicz A, Eng C, Opocher G, Neumann HPH: Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHD gene. JAMA 2005, 294:2057-2063                      
  • Imdahl A, Brink I: Reply to the comments by Dr Junginger and Dr Kneist regarding our publication “Impact of FDG-PET for staging of esophageal cancer” [letter]. Langenbecks Archive of  Surgery 2005, 390(2): 180-181 
  • Bley TA, Zeiser R, Ghanem NA, Hackanson B, Brink I, Langer M. High grade cardiac lymphoma vitality monitoring by gadolinium-enhanced Magnetic resonance imaging (MRI). In vivo International journal of experimental and clinical pathophysiology and  drug research 2005, 19: 689-694  
  • Ghanem N, Uhl M, Brink I, Schaefer O, Kelly T, Moser E, Langer M. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone (review). Eur J Radiol 2005, 55(1): 41-55 
  • Schindler TH, Nitzsche EU, Schelbert HR, Olschewski M, Sayre J, Mix M, Brink I, Zhang XL, Kreissl M, Magosaki N, Just H, Solzbach U: PET-Measurement abnormal responses of myocardial blood flow to sympathetic stimulation are associated with the risk of developing cardiovascular events. J Am Coll Cardiol 2005, 45(9):1505-12    
  • Belhocine T, Weiner SM, Brink I, De Deyn PP, Roland J, Borght TV, Flamen P: A plea for the elective inclusion of the brain into routine whole-body FDG PET. Eur J Nucl Med Mol Imaging 2005, 32:251-256     
  • Yamada K, Brink I, Bisse E, Epting T, Engelhardt R: Factors influencing FDG uptake in melanoma cells: 1) The role of proliferation rate, viability, glucose transporter expression and hexokinase activity. J Dermatol 2005, 32 (5): 316-334   
  • Yamada K, Brink I, Engelhardt R: Factors influencing FDG accumulation in melanoma cells: 2) Is FDG a substrate of multidrug resistance (MDR)? J Dermatol 2005, 32 (5): 335-345     
  • Hentschel M, Paul D, Korsten-Reck U, Mix M, Müller F, Merk S, Moser E, Brink I: Can body volume be determined by PET?  Eur J Nucl Med 2005, 32:564-568     
  • Ströbel P, Hartmann M, Jakob A, Mikesch K, Brink I, Dirnhofer S, Marx A. Thymic Carcinoma with Over-Expression of mutated KIT: Response to Imatinib. N Engl J Med 2004, 350(25): 2625-2626 (letter)           
  • Deschler B, Reincke M, Bley TA, Brink I, Engelhardt M. Striking complete remission after interferon-alpha for secondary recurrent non-Hodgkin's lymphoma but rare interferon-induced side effects. Ann Hematol 2005, 84:262-266   
  • Magosaki E, Schäfer DM, Magosaki N, Handke M, Heinrichs G, Schöchlin A, Brink I, Bode C, Geibel A: Optimal number of image slices for reliable measurement of left ventricular volumes and ejection fraction by three-dimensional transesophageal echocardiography. J Med Ultrasonics 2004, 31: 59-65   
  • Imdahl A, Hentschel M, Kleimaier M, Hopt UT, Brink I: Impact of FDG-PET for staging of esophageal cancer. Langenbecks Archive of  Surgery 2004, 389(4): 283-288 
  • Schindler TH, Nitzsche EU, Olschewski M, Brink I,  Mix M, Prior J, Facta A, Just HJ, Schelbert HR: PET-measured Responses in Myocardial Blood Flow to Cold Pressor Testing Correlate with Indices of Coronary Vasomotion on Quantitative Coronary Angiography. J Nucl Med 2004; 45: 419-428  
  • Weiner SM, Vaith P, Walker UA, Brink I: Alterations of brain glucose metabolism detected by positron emission tomography in Takayasu's arteritis. Comment on "Imaging of large vessel vasculitis with 18 FDG PET: illusion or reality? A critical review of the literature data" by Belhocine et al. Eur J Nucl Med Mol Imaging 2004, 31: 300-302 (letter)   
  • Schindler TH, Brink I,  Mix M, Olschewski M, Magosaki N, Just HJ, Nitzsche EU:"Coronary Vasoregulation in Patients with Various Risk Factors in Response to Cold Pressor Testing: Contrasting Myocardial Blood Flow Responses to Short- and Long-Term Vitamin C Administration. JACC 2003, 42:814-822    
  • Hoegerle S, Ghanem N, Altehoefer C, Schipper J, Brink I, Moser E, Neumann HPH:  18F DOPA positron emission tomography for detection of glomus tumors: comparison to MRI. Eur J Nucl Med Mol Imaging 2003, 30: 689-694 
  • Weiner S, Otte A, Uhl M, Brink I, Schumacher M, Peter HH: Neuropsychiatrische Beteiligung des systemischen Lupus Erythematodes. Teil 2: Diagnostik und Therapie. Medizinische Klinik 2003, 98: 79-90 (review)   
  • Hentschel M, Brink I: Lean body mass-based standardized uptake value, derived from a predictive equation, might be misleading in PET studies. Eur J Nucl Med Mol Imaging 2003, 30:473-474 (letter) 
  • Schindler Th, Nitzsche E, Magosaki N, Brink I, Mix M, Olschewski M, Solzbach U, Just HJ: Regional Myocardial Perfusion Defects during Exercise as assessed by 3D Integration of Morphology and Function in Relation to Abnormal Endothelial-Dependent Vasoreactivity of Coronary Microcirculation. Heart 2003;89:517-526                    
  • Reinhardt MJ, Brink I, Joe AY, von Mallek D, Ezziddin S, Palmedo H, Krause T: Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med Mol Imaging 2002, 29:1118-1124        
  • Nitzsche EU, Hoegerle S, Mix M, Brink I, Otte A, Moser E, Imdahl A: Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantititive uptake value analysis. Eur J Nucl Med Mol Imaging 2002, 29:237-242   
  • Schumacher T, Brink I, Mix M, Reinhardt M, Herget G, Digel W, Henke M, Moser E, Nitzsche EU: FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 2001, 28: 483-488           
  • Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, Reincke M, Moser E, Neumann HPH: 18Fluoro DOPA whole-body positron emission tomography for detection of pheochromocytomas: initial results. Radiology 2002, 222:507-512                     
  • Zajic T, Fischer R, Saurbier B, Brink I, Moser E, Krause T: Die Myokardperfusions-szintigraphie zur Bestimmung der linksventrikulären Funktion und Herzvolumina – zwei  Auswerteverfahren im Vergleich. Nuklearmedizin 2001, 40:135-142                     
  • Imdahl A, Jenkner S, Brink I, Nitzsche EU, Stoelben E, Moser E, Hasse J: Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions. Eur J Cardiothorac Surg 2001, 20:324-329                
  • Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E: 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001, 28:64-71                    
  • Weiner S, Otte A, Schumacher M, Jüngling F, Brink I, Nitzsche EU, Peter HH, Kreisel W: Neuro-Behcet syndrome in a patient not fulfilling criteria for Behcet disease: clinical features and value of brain imaging. Clin Rheumatol 2000, 19:231-234
  • Weiner S, Otte A, Schumacher M, Klein R, Gutfleisch J, Otto P, Brink I, Nitzsche EU, Peter HH: Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus and primary Sjogren’s syndrom: value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis 2000, 59:377-385               
  • Weiner S, Otte A, Schumacher M, Brink I, Jüngling F, Sobanski T, Nitzsche EU, Peter HH: Alterations of cerebral glucose metabolism indicate progress to severe morphological brain lesion in neuropsychiatric systemic lupus erythematosus. Lupus 2000, 9:386-389
  • Tashiro M, Juengling FF, Reinhardt MJ, Brink I, Hoegerle S, Mix M, Kubota K, Yamaguchi K, Itoh M, Sasaki H, Moser E, Nitzsche EU: Reproducibility of PET Brain Mapping of Cancer Patients. J Psycho-Oncology 2000; 9(2):157-163                      
  • Schumacher T, Brink I, Moser E, Nitzsche EU: Darstellung eines Nebennierenkarzinoms mit seinen Metastasen mit FDG-PET. Nuklearmedizin 1999, 38:124-126       
  • Buttgereit F, Brink I, Thiele B, Burmester GR, Hiepe F, Hall ED: Effects of methylprednisolone and 21-aminosteroids on mitogen-induced interleukin-6 and tumor necrosis factor-alpha production in human peripheral blood mononuclear cells. Journal of Pharmacology & Experimental Therapeutics. 275(2):850-3, 1995   
  • Thiele B, Brink I, Ploch M: Modulation of cytokine expression by hypericum extract. Journal of Geriatric Psychiatry & Neurology. 7 Suppl 1:S60-2, 1994